Cargando…

Comparative Genomic Landscape of Urothelial Carcinoma of the Bladder Among Patients of East and South Asian Genomic Ancestry

BACKGROUND: Despite the low rate of urothelial carcinoma of the bladder (UCB) in patients of South Asian (SAS) and East Asian (EAS) descent, they make up a significant portion of the cases worldwide. Nevertheless, these patients are largely under-represented in clinical trials. We queried whether UC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peak, Taylor, Spiess, Philippe E, Li, Roger, Grivas, Petros, Necchi, Andrea, Pavlick, Dean, Huang, Richard S P, Lin, Douglas, Danziger, Natalie, Jacob, Joseph M, Bratslavsky, Gennady, Ross, Jeffrey S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Genitourinary Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546831/ https://www.ncbi.nlm.nih.gov/pubmed/37196060 http://dx.doi.org/10.1093/oncolo/oyad120

Ejemplares similares

Comprehensive Genomic Profiling of NF2-Mutated Kidney Tumors Reveals Potential Targets for Therapy
por: Hacking, Sean M, et al.
Publicado: (2023)

The Rapidly Evolving Landscape of First‐Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review
por: Lavoie, Jean‐Michel, et al.
Publicado: (2021)

Advanced Squamous Cell Carcinomas of the Pelvic and Perineal Region: A Comprehensive Genomic Profiling Study
por: Necchi, Andrea, et al.
Publicado: (2022)

Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer
por: Garje, Rohan, et al.
Publicado: (2020)

HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese Population
por: Zhou, Li, et al.
Publicado: (2023)

Stereotactic body radiation therapy for medically inoperable, clinically localized, urothelial carcinoma of the renal pelvis: A case report
por: Evans, Jaden D., et al.
Publicado: (2017)

Clinical and Economic Outcomes in Patients With Metastatic Urothelial Carcinoma Receiving First-Line Systemic Treatment (the IMPACT UC I Study)
por: Bilen, Mehmet A, et al.
Publicado: (2023)

First-Line Treatments for Metastatic Clear Cell Renal Cell Carcinoma: An Ever-Enlarging Landscape
por: Gulati, Shuchi, et al.
Publicado: (2022)

Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer
por: Freeman, Meredith N, et al.
Publicado: (2022)

Comprehensive Landscape of Cyclin Pathway Gene Alterations and Co-occurrence with FGF/FGFR Aberrations Across Urinary Tract Tumors
por: Jardim, Denis L F, et al.
Publicado: (2022)

A report of two deep-seated noncutaneous penile tumors: more than meets the eye
por: Thomas, Kerry, et al.
Publicado: (2017)

Four Cycles of Etoposide plus Cisplatin for Patients with Good‐Risk Advanced Germ Cell Tumors
por: Funt, Samuel A., et al.
Publicado: (2021)

The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer
por: Castro, Elena, et al.
Publicado: (2016)

Treatment options for advanced urothelial cancer after progression on chemotherapy and immune checkpoint inhibitors: a literature review
por: Koshkin, Vadim S., et al.
Publicado: (2021)

Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer
por: Antonarakis, Emmanuel S., et al.
Publicado: (2016)

Salvage image guided radiation therapy to the prostate after cryotherapy failure
por: Hopper, Austin B., et al.
Publicado: (2017)

Late toxicity after post-prostatectomy intensity modulated radiation therapy: Evaluating normal-tissue sparing guidelines
por: Akthar, Adil S., et al.
Publicado: (2018)

Initial toxicity, quality-of-life outcomes, and dosimetric impact in a randomized phase 3 trial of hypofractionated versus standard fractionated proton therapy for low-risk prostate cancer
por: Vargas, Carlos E., et al.
Publicado: (2018)

Radiomics-guided therapy for bladder cancer: Using an optimal biomarker approach to determine extent of bladder cancer invasion from t2-weighted magnetic resonance images
por: Tong, Yubing, et al.
Publicado: (2018)

Prostate Stereotactic Body Radiation Therapy With a Focal Simultaneous Integrated Boost: Acute Toxicity and Dosimetry Results From a Prospective Trial
por: McDonald, Andrew M., et al.
Publicado: (2018)

Transitioning From a Low-Dose-Rate to a High-Dose-Rate Prostate Brachytherapy Program: Comparing Initial Dosimetry and Improving Workflow Efficiency Through Targeted Interventions
por: Solanki, Abhishek A., et al.
Publicado: (2018)

The Perineural Invasion Paradox: Is Perineural Invasion an Independent Prognostic Indicator of Biochemical Recurrence Risk in Patients With pT2N0R0 Prostate Cancer? A Multi-Institutional Study
por: Kraus, Ryan Douglas, et al.
Publicado: (2018)

Percutaneous Image-Guided Nodal Biopsy After 11C-Choline PET/CT for Biochemically Recurrent Prostate Cancer: Imaging Predictors of Disease and Clinical Implications
por: Welch, Brian T., et al.
Publicado: (2018)

Analysis of Gastrointestinal Toxicity in Patients Receiving Proton Beam Therapy for Prostate Cancer: A Single-Institution Experience
por: Lee, Howard J., et al.
Publicado: (2018)

Radiation-related Lymphopenia after Pelvic Nodal Irradiation for Prostate Cancer
por: Schad, Michael D., et al.
Publicado: (2019)

Early Tolerance Outcomes of Stereotactic Hypofractionated Accelerated Radiation Therapy Concomitant with Pelvic Node Irradiation in High-risk Prostate Cancer
por: Pinitpatcharalert, Attapol, et al.
Publicado: (2019)

Regional Differences in the Treatment of Localized Prostate Cancer: An Analysis of Surgery and Radiation Utilization in the United States
por: Scherzer, Nickolas D., et al.
Publicado: (2019)

Dose-Escalated Intensity Modulated Radiation Therapy for Prostate Cancer: 15-Year Outcomes Data
por: Weg, Emily S., et al.
Publicado: (2019)

Pathologic Complete Response After Chemoradiation of a Massive Primary Urethral Carcinoma
por: Singh, Tanmay, et al.
Publicado: (2019)

Evaluating the potential benefit of reduced planning target volume margins for low and intermediate risk patients with prostate cancer using real-time electromagnetic tracking
por: Chaurasia, Avinash R., et al.
Publicado: (2018)

Stereotactic body radiation therapy for adrenal gland metastases: Outcomes and toxicity
por: Toesca, Diego A.S., et al.
Publicado: (2018)

Building a High-Dose-Rate Prostate Brachytherapy Program With Real-Time Ultrasound-Based Planning: Initial Safety, Quality, and Outcome Results
por: Zhang, Hong, et al.
Publicado: (2020)

Ten-Year Results From a Phase II Study on Image Guided, Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost in High-Risk Prostate Cancer
por: Ekanger, Christian, et al.
Publicado: (2019)

Gantry-Mounted Linear Accelerator–Based Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer
por: Dang, Audrey T., et al.
Publicado: (2019)

Long‐Term Experience of Chemoradiotherapy Combined with Deep Regional Hyperthermia for Organ Preservation in High‐Risk Bladder Cancer (Ta, Tis, T1, T2)
por: Merten, Ricarda, et al.
Publicado: (2019)

Assessment of Polyethylene Glycol Hydrogel Spacer and Its Effect on Rectal Radiation Dose in Prostate Cancer Patients Receiving Proton Beam Radiation Therapy
por: Navaratnam, Anojan, et al.
Publicado: (2019)

Utilization of Stereotactic Ablative Body Radiation Therapy for Intact Renal Cell Carcinoma: Trends in Treatment and Predictors of Outcome
por: Wegner, Rodney E., et al.
Publicado: (2019)

Dosimetric Evaluation of PSMA PET-Delineated Dominant Intraprostatic Lesion Simultaneous Infield Boosts
por: Goodman, Christopher D., et al.
Publicado: (2019)

Nephron-Sparing Robotic Radiosurgical Therapy for Primary Renal Cell Carcinoma: Single-Institution Experience and Review of the Literature
por: Peddada, Anuj V., et al.
Publicado: (2019)

Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
por: Martini, Dylan J., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_80k1efj1rg7n1k8ad4krhjb2gu